Onderneming Vinings Holdings Inc. Other OTC
Aandelen
NDYN
US92744A1051
Farmaceutische producten
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28-10-22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17-05-23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28-10-22 |
Colleen Delaney
CTO | Chief Tech/Sci/R&D Officer | 57 | 30-08-23 |
Christine Sheehy
CMP | Compliance Officer | 57 | 28-10-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 62 | 28-10-22 | |
Director/Board Member | 55 | 28-10-22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28-10-22 |
Gene Salkind
BRD | Director/Board Member | 70 | 28-10-22 |
Chris Calise
BRD | Director/Board Member | 51 | 28-10-22 |
David Mehalick
CEO | Chief Executive Officer | 56 | 28-10-22 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28-10-22 |
Director/Board Member | 56 | 28-10-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 37 118 593 | 25 373 891 ( 68,36 %) | 0 | 68,36 % |
Bedrijfsgegevens
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road Suite 420
15090, Wexford
+
http://www.coeptistx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+42,55% | 739 mld. | |
+32,34% | 598 mld. | |
-5,67% | 353 mld. | |
+17,64% | 318 mld. | |
+3,64% | 285 mld. | |
+16,47% | 240 mld. | |
+9,26% | 210 mld. | |
-5,07% | 206 mld. | |
+6,73% | 164 mld. |